• Capture-and-Release Enhances Lateral Flow Assay Sensitivity

  2026-04-28

  The referenced study introduces a 'capture-and-release' AmpliFold workflow that significantly enhances the sensitivity of lateral flow assays (LFAs) by enabling high-affinity rebinding of target complexes. This approach leverages cleavable linkers and dual-affinity nanoparticles, offering a tractable method to overcome kinetic limitations in point-of-care diagnostics.

• Polyether Ionophore Toxicity: Mechanisms, Structure, and Imp

  2026-04-28

  This review synthesizes recent advances in the understanding of polyether ionophore toxicity in animals, with a focus on clinical and molecular mechanisms. The findings clarify how ionophore structure underpins cation transport and toxicity, informing both veterinary safety and emerging research applications.

• 3D Shell MEAs Advance Human Cardiac Organoid Electrophysiolo

  2026-04-27

  This study introduces programmable shell microelectrode arrays (MEAs) that enable comprehensive 3D electrophysiological mapping of cardiac organoids. The technology provides high-resolution, organoid-spanning data, overcoming the limitations of 2D MEAs and supporting advanced cardiac disease modeling and pharmacological testing.

• Low-Molecular Weight Inhibitors Targeting the Alternative Co

  2026-04-27

  This review by Schubart et al. details the development and mechanistic underpinnings of low-molecular weight (LMW) inhibitors for the alternative complement pathway, emphasizing their selectivity for factor B and D. The findings provide foundational guidance for researchers seeking to modulate complement activation in both systemic and tissue-specific diseases driven by pathway dysregulation.

• FAM83A Regulates Mitochondrial Integrity in White Adipogenes

  2026-04-26

  This study uncovers a pivotal role for the proto-oncogene FAM83A in maintaining mitochondrial function and promoting white adipocyte differentiation. Using targeted gene delivery, the authors demonstrate that FAM83A knockdown disrupts mitochondrial processes, impedes lipid accumulation, and confers resistance to diet-induced obesity—offering mechanistic insight into adipocyte biology and metabolic disease modulation.

• Biotin Azide: Precision Bio-Orthogonal Labeling for Affinity

  2026-04-25

  Biotin Azide (N-(3-azidopropyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide) streamlines biotin labeling of alkynylated biomolecules with unrivaled specificity via copper-catalyzed click chemistry. Its robust solubility, high purity, and bio-orthogonal mechanism empower advanced affinity purification and detection strategies, as validated by both published research and APExBIO's stringent product benchmarks.

• Bay 11-7821 (BAY 11-7082): Precise Tool for NF-κB Pathway Re

  2026-04-24

  Bay 11-7821 (BAY 11-7082) is a selective IKK inhibitor widely used to dissect inflammatory signaling and apoptosis regulation. This compound demonstrates robust inhibition of NF-κB activation, shows in vivo efficacy in tumor models, and enables reproducible cancer and immunology research workflows. Evidence-based protocols and solubility parameters make it an indispensable reagent for translational studies.

• CPSIT_0844 Drives IL-6/IL-8 via TLR2/4–NF-κB in Monocytes

  2026-04-24

  This study uncovers how the Chlamydia psittaci inclusion membrane protein CPSIT_0844 triggers robust inflammatory cytokine production in human monocytes through TLR2/TLR4–MyD88-dependent activation of MAPK and NF-κB pathways. These mechanistic insights clarify the molecular underpinnings of C. psittaci-induced immunopathology and highlight potential targets for modulating inflammation in infectious diseases.

• Pexmetinib (ARRY-614): Data-Driven Solutions for Cytokine As

  2026-04-23

  This article offers practical, scenario-based guidance for biomedical researchers and laboratory teams utilizing Pexmetinib (ARRY-614) (SKU B6012). Through real-world Q&A, it demonstrates how this dual inhibitor enhances reproducibility and sensitivity in cytokine and cell viability assays, with evidence-backed recommendations for protocol optimization and vendor reliability.

• Ibotenic Acid: NMDA Receptor Agonist for Advanced Neurodegen

  2026-04-23

  Ibotenic acid enables reproducible animal models of neurodegenerative disorders and precise circuit-mapping, thanks to its high water solubility and validated NMDA receptor agonist activity. APExBIO’s high-purity B6246 streamlines experimental setups and delivers consistent results for translational neuroscience research.

• Decitabine (5-Aza-2'-deoxycytidine) in Cancer Epigenetics Wo

  2026-04-22

  Decitabine (5-Aza-2'-deoxycytidine) empowers precise tumor suppressor gene reactivation and robust DNA methylation modulation in both hematopoietic and solid tumor research. This article delivers applied protocols, troubleshooting tips, and new insights from recent studies, enabling reproducibility and translational impact in cancer epigenetic experiments.

• METTL14-m6A-lncRNA Axis Regulates Inflammation in Ulcerative

  2026-04-22

  Wu et al. (2024) demonstrate that METTL14-mediated m6A modification of lncRNA DHRS4-AS1 suppresses inflammation in ulcerative colitis via the DHRS4-AS1/miR-206/A3AR signaling axis. These findings identify a novel epigenetic regulatory pathway influencing inflammatory injury, highlighting METTL14 as a potential therapeutic target for UC.

• Applied Workflows with EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

  2026-04-21

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables direct, dual-channel tracking of mRNA delivery and translation efficiency, transforming gene regulation and cell imaging studies. Its immune-evasive modifications and robust fluorescence outperform traditional reporter RNAs for troubleshooting and optimizing transfection workflows.

• Chlorpromazine: Mechanisms, Research Benchmarks, and Pitfall

  2026-04-21

  Chlorpromazine is a prototypical antipsychotic used in research to elucidate dopamine receptor signaling and antiemetic mechanisms. This article details its receptor antagonism, solubility, and validated use cases, clarifying common misconceptions and integration strategies for biomedical assays.

• Tropifexor (LJN452): FXR Agonist for Intestinal Barrier and

  2026-04-20

  Explore Tropifexor (LJN452) as a potent tool for FXR signaling and advanced intestinal barrier function research. Discover unique insights into anti-fibrotic mechanisms, practical protocol parameters, and applications distinct from previous reviews.

15807 records 1/1054 page Next 12345 下5页 Last page